Pfizer-Olema Collaboration Targets Metastatic Breast Cancer

Group 1 - Pfizer Inc. is considered an undervalued stock with a strong market position and is currently a recommended buy [1] - Olema Pharmaceuticals has entered into a collaboration and supply agreement with Pfizer for the treatment of metastatic breast cancer, focusing on the palazestrant-atirmociclib combination in a clinical trial involving approximately 35 patients, expected to start in H2 2025 [1][2] - Pfizer will supply atirmociclib for the Phase 1b/2 study led by Olema, with the aim of establishing palazestrant as a potential backbone endocrine therapy for metastatic breast cancer [2] Group 2 - Pfizer has shown financial resilience with improved profit margins, expanding cash flows, and a stronger balance sheet, contributing to its stable dividend [2] - The company is actively pursuing new acquisitions and partnerships to support its growth outlook for 2030 [2] - Pfizer is a biopharmaceutical company that has been committed to developing transformative medicines and vaccines since its founding in 1849 [3]